Grant: Master's Award: Canada Graduate Scholarships
University of Toronto
$17,500.00
Characterization of Pre-Leukemic Stem Cells in Human Acute Myeloid Leukemia
EF 2017-18
Résumé
Acute myeloid leukemia (AML) is a deadly blood cancer that progresses rapidly and frequently relapses in response to chemotherapy. To develop more effective treatments for AML, it is crucial to understand both how it develops and how it responds to therapy. Recent studies have identified the ancestors of AML: mutant blood stem cells in the bone marrow called pre-leukemic stem cells. Pre-leukemic stem cells are capable of out-dividing normal blood stem cells and are predisposed to transforming into full-fledged AML; they are also spared by chemotherapy and may drive relapse of AML after therapy-induced remission. To understand how pre-leukemic stem cells differ from normal blood stem cells, as well as the biological basis for their transformation into AML, I will use whole blood samples from AML patients collected years before they develop leukemia. I will isolate the stem cells from these whole blood samples, which contain a mixture of pre-leukemic stem cells and normal blood stem cells. I will transplant these cells into mice in order to assess the functional differences between pre-leukemic and normal stem cells. I will also employ single-cell RNA sequencing in order to understand the differences in gene expression between pre-leukemic and normal stem cells. By finding networks of genes that are specifically expressed in pre-leukemic stem cells, we can identify drug targets that allow us to prevent the transformation of pre-leukemic stem cells into AML. Ultimately, this work will constitute a critical step towards predicting and preventing both the occurrence and relapse of human AML.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
386596
Name
Zeng Andy G
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Characterization of Pre-Leukemic Stem Cells in Human Acute Myeloid Leukemia
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Acute Myeloid Leukemia; Hematopoietic Stem Cells; Leukemogenesis; Pre-Leukemia; Relapse
Abstract
Acute myeloid leukemia (AML) is a deadly blood cancer that progresses rapidly and frequently relapses in response to chemotherapy. To develop more effective treatments for AML, it is crucial to understand both how it develops and how it responds to therapy. Recent studies have identified the ancestors of AML: mutant blood stem cells in the bone marrow called pre-leukemic stem cells. Pre-leukemic stem cells are capable of out-dividing normal blood stem cells and are predisposed to transforming into full-fledged AML; they are also spared by chemotherapy and may drive relapse of AML after therapy-induced remission. To understand how pre-leukemic stem cells differ from normal blood stem cells, as well as the biological basis for their transformation into AML, I will use whole blood samples from AML patients collected years before they develop leukemia. I will isolate the stem cells from these whole blood samples, which contain a mixture of pre-leukemic stem cells and normal blood stem cells. I will transplant these cells into mice in order to assess the functional differences between pre-leukemic and normal stem cells. I will also employ single-cell RNA sequencing in order to understand the differences in gene expression between pre-leukemic and normal stem cells. By finding networks of genes that are specifically expressed in pre-leukemic stem cells, we can identify drug targets that allow us to prevent the transformation of pre-leukemic stem cells into AML. Ultimately, this work will constitute a critical step towards predicting and preventing both the occurrence and relapse of human AML.
Competitiondate
201712
Approvedterm2
1 yr 0 mth
Pinamesdelim
Zeng, Andy G
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~